Leerink Partners analyst Puneet Souda maintained a Buy rating on Castle Biosciences (NASDAQ:CSTL) on Monday, setting a price target of $80, which is approximately 53.52% above the present share price of $52.11.
Souda expects Castle Biosciences to post earnings per share (EPS) of -$0.23 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Castle Biosciences, with an average price target of $86.2.
The analysts price targets range from a high of $94 to a low of $73.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $17.3 million and a net profit of -$3.03 million. The company's market cap is $1.31 billion.
According to TipRanks.com, Leerink Partners analyst Puneet Souda is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 13.4% and a 51.20% success rate.
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.